Özet:

Purpose: In our study, we wanted to evaluate the results of one-center magnetic resonance imaging-ultrasonic fusion prostate biopsy (MRI-US FPBx) and compare it with current literature. The MRI-US FPBx results of 358 men between January 2016 and July 2019 were analyzed retrospectively. PI-RADS scores were detected in 222 (% 62), 107 (% 29.8) and 29 (% 8.1) patients, respectively, as 3, 4 and 5. A total of 454 injuries were applied to MRI-US FPBx. 303 (% 66.7) injury PI-RADS 3, 120 (% 26.4) injury PI-RADS 4 and 31 (% 6.8) injury PI-RADS 5 was scored. 315 of the injuries were in the peripheral zone (69.3%), 26 (5.7%) in the central zone, 111 (24.4%) in the transition zone and 2 in the anterior fibromuscular stroma. Results: General prostate cancer (PCa) detection rate was 36.3%. MRI-US FPBx alone and transrectal ultrasound alone accompanied by prostate biopsy (TRUS-Bx) cancer detection rates were 27.6% and 26.5% respectively. For PI-RADS-3 and PI-RADS 4 & 5, the MRI-US FPBx-specific cancer detection rate was 6.9% and 20.6% respectively. The rates of clinically significant prostate cancer (csPCa) were evaluated and the rates of CSPCa and PCa for TRUS-Bx, MRI-US FPBx and combined techniques were respectively 16.8%, 35.4 and 39.2%. The results of the biopsy of 11 patients were benign. The result: MRI-US FPBx significantly increases the success rate of the prostate biopsy procedure. However, according to the current MRI technology, we believe it is not appropriate to consider MRI-US FPBx as an independent biopsy option without TRUS-Bx.

Anahtar Kelimeler: